UBS Group’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $582K | Sell |
89,475
-34,701
| -28% | -$226K | ﹤0.01% | 4728 |
|
|
2025
Q1 | $985K | Buy |
124,176
+59,949
| +93% | +$475K | ﹤0.01% | 4204 |
|
|
2024
Q4 | $814K | Sell |
64,227
-50,410
| -44% | -$639K | ﹤0.01% | 4364 |
|
|
2024
Q3 | $1.6M | Buy |
114,637
+44,554
| +64% | +$621K | ﹤0.01% | 3215 |
|
|
2024
Q2 | $966K | Sell |
70,083
-93,935
| -57% | -$1.29M | ﹤0.01% | 3431 |
|
|
2024
Q1 | $2.71M | Buy |
164,018
+37,378
| +30% | +$617K | ﹤0.01% | 2716 |
|
|
2023
Q4 | $1.85M | Buy |
126,640
+102,759
| +430% | +$1.5M | ﹤0.01% | 2935 |
|
|
2023
Q3 | $293K | Buy |
23,881
+11,338
| +90% | +$139K | ﹤0.01% | 3986 |
|
|
2023
Q2 | $150K | Sell |
12,543
-57,322
| -82% | -$684K | ﹤0.01% | 4643 |
|
|
2023
Q1 | $934K | Sell |
69,865
-59,992
| -46% | -$802K | ﹤0.01% | 3232 |
|
|
2022
Q4 | $2.79M | Buy |
129,857
+108,251
| +501% | +$2.33M | ﹤0.01% | 2285 |
|
|
2022
Q3 | $432K | Buy |
21,606
+17,755
| +461% | +$355K | ﹤0.01% | 3491 |
|
|
2022
Q2 | $69K | Buy |
+3,851
| New | +$69K | ﹤0.01% | 4688 |
|
|
2022
Q1 | – | Sell |
-6,103
| Closed | -$103K | – | 9229 |
|
|
2021
Q4 | $103K | Buy |
6,103
+6,044
| +10,244% | +$102K | ﹤0.01% | 5222 |
|
|
2021
Q3 | $1K | Buy |
+59
| New | +$1K | ﹤0.01% | 8009 |
|